Table 5.
Risk of secondary outcomes for abatacept versus TNFi initiators: 1:1 PS-matched analysis for as-treated (<30 days gap)
| Abatacept (N=11,248) | TNFi (N=11,248) | |||||||
|---|---|---|---|---|---|---|---|---|
| No. Events | Person-Years | IR, per 1000 PY (95% CI) | HR (95% CI) | No. Events | Person-years | IR, per 1000 PY | HR (95% CI) | |
|
Bacterial infection |
100 |
5,160 |
19.4 (15.9–23.6) |
0.81 (0.62–1.06) |
112 |
4,621 |
24.0 (20.0–28.9) |
1.0 |
| Herpes zoster | 81 | 5,141 | 15.8 (12.7–19.6) | 1.00 (0.73–1.37) | 73 | 4,639 | 15.7 (12.5–19.8) | 1.0 |
|
By organ system | ||||||||
| Bone/Joint | 7 | 5,190 | 1.4 (0.6–2.8) | 0.91 (0.32–2.60) | 7 | 4,696 | 1.5 (0.7–3.1) | 1.0 |
| Cardiac | 0 | 5,191 | - | - | 1 | 4,697 | 0.2 (<0.1–1.5) | 1.0 |
| Gastrointestinal | 20 | 5,186 | 3.9 (2.5–6.0) | 0.75 (0.41–1.35) | 24 | 4,689 | 5.1 (3.4–7.6) | 1.0 |
| Genitourinary | 17 | 5,185 | 3.3 (2.0–5.3) | 1.04 (0.52–2.07) | 15 | 4,690 | 3.2 (1.9–5.3) | 1.0 |
| Respiratory | 65 | 5,160 | 12.6 (9.9–16.1) | 0.71 (0.52–0.99) | 83 | 4,666 | 17.8 (14.4–22.1) | 1.0 |
| Skin/soft tissue | 30 | 5,179 | 5.8 (4.1–8.3) | 0.68 (0.42–1.09) | 40 | 4,683 | 8.5 (6.3–11.6) | 1.0 |
| Neurologic | 1 | 5,191 | 0.2 (<0.1–1.4) | 0.91 (0.06–14.5) | 1 | 4,697 | 0.2 (<0.1–1.5) | 1.0 |